Client Work Detail

On March 3, 2008, Æterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, and Paladin Labs Inc., a leading Canadian specialty pharmaceutical company, announced that they had entered into a definitive purchase and sale agreement with respect to the sale by Æterna Zentaris to Paladin Labs of all rights related to the manufacture, production, distribution, marketing, sale and/or use of miltefosine for an aggregate purchase price of Cdn$9.125 million payable in cash, subject to certain post-closing purchase price adjustments. Completion of the transactions contemplated by the purchase agreement is subject to customary closing conditions, including the parties having received certain third-party consents and approvals.